Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy